ZA938676B - Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht antagonists - Google Patents

Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht antagonists

Info

Publication number
ZA938676B
ZA938676B ZA938676A ZA938676A ZA938676B ZA 938676 B ZA938676 B ZA 938676B ZA 938676 A ZA938676 A ZA 938676A ZA 938676 A ZA938676 A ZA 938676A ZA 938676 B ZA938676 B ZA 938676B
Authority
ZA
South Africa
Prior art keywords
pct
date jun
represents hydrogen
sec
formula
Prior art date
Application number
ZA938676A
Other languages
English (en)
Inventor
Georges Henri Paul Van Daele
Jean-Paul Rene Marie A Bosmans
Willy Joannes Carolu Laerhoven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA938676B publication Critical patent/ZA938676B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Dental Preparations (AREA)
ZA938676A 1992-11-20 1993-11-19 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht antagonists ZA938676B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20

Publications (1)

Publication Number Publication Date
ZA938676B true ZA938676B (en) 1995-05-19

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA938676A ZA938676B (en) 1992-11-20 1993-11-19 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht antagonists

Country Status (31)

Country Link
US (2) US5674868A (cs)
EP (1) EP0669919B1 (cs)
JP (1) JP2830952B2 (cs)
KR (1) KR0166661B1 (cs)
AT (1) ATE176232T1 (cs)
AU (1) AU680640B2 (cs)
BG (1) BG62489B1 (cs)
BR (1) BR9307477A (cs)
CA (1) CA2149044C (cs)
CZ (1) CZ287262B6 (cs)
DE (1) DE69323322T2 (cs)
DK (1) DK0669919T3 (cs)
ES (1) ES2129615T3 (cs)
FI (1) FI952458A7 (cs)
GR (1) GR3029831T3 (cs)
HU (2) HUT72740A (cs)
IL (3) IL119273A0 (cs)
LV (1) LV10956B (cs)
MX (1) MX9307257A (cs)
NO (2) NO307690B1 (cs)
NZ (1) NZ257854A (cs)
OA (1) OA10158A (cs)
PL (1) PL176051B1 (cs)
RO (1) RO115160B1 (cs)
RU (1) RU2116072C1 (cs)
SG (1) SG47488A1 (cs)
SK (1) SK282378B6 (cs)
TW (1) TW294595B (cs)
UA (1) UA49792C2 (cs)
WO (1) WO1994012494A1 (cs)
ZA (1) ZA938676B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
CA2286076C (en) 1997-04-18 2006-12-12 Janssen Pharmaceutica N.V. Use of 5ht3 antagonists for promoting intestinal lavage
PL190296B1 (pl) * 1997-07-11 2005-11-30 Janssen Pharmaceutica Nv Zastosowanie (+)-norcyzaprydu
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
CN1882549B (zh) 2003-11-20 2011-02-23 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮
EP1687277B1 (en) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
EA012416B1 (ru) 2004-06-30 2009-10-30 Янссен Фармацевтика Н.В. Производные замещенного 2-алкилхиназолинона как ингибиторы parp
NZ551799A (en) 2004-06-30 2009-11-27 Janssen Pharmaceutica Nv Phthalazine derivatives as PARP inhibitors
ES2415771T3 (es) 2004-06-30 2013-07-26 Janssen Pharmaceutica N.V. Derivados de quinazolina como inhibidores de PARP
EP2134691B1 (en) 2007-03-08 2012-01-25 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp and tank inhibitors
JP5525447B2 (ja) 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
AU2009228943B2 (en) 2008-03-27 2013-04-04 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
ATE513818T1 (de) 2008-03-27 2011-07-15 Janssen Pharmaceutica Nv Chinazolinonderivate als tubulinpolymerisationshemmer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
SK67595A3 (en) 1995-11-08
RO115160B1 (ro) 1999-11-30
IL107654A (en) 1998-01-04
BG62489B1 (bg) 1999-12-30
RU2116072C1 (ru) 1998-07-27
JP2830952B2 (ja) 1998-12-02
EP0669919A1 (en) 1995-09-06
HUT72740A (en) 1996-05-28
ATE176232T1 (de) 1999-02-15
LV10956B (en) 1996-10-20
GR3029831T3 (en) 1999-06-30
KR0166661B1 (ko) 1999-01-15
BR9307477A (pt) 1999-06-29
CA2149044A1 (en) 1994-06-09
MX9307257A (es) 1994-05-31
UA49792C2 (uk) 2002-10-15
LV10956A (lv) 1995-12-20
WO1994012494A1 (en) 1994-06-09
CZ125895A3 (en) 1995-10-18
NO308530B1 (no) 2000-09-25
NZ257854A (en) 1997-04-24
AU680640B2 (en) 1997-08-07
AU5465994A (en) 1994-06-22
RU95113434A (ru) 1997-03-10
HU211546A9 (en) 1995-12-28
ES2129615T3 (es) 1999-06-16
NO995762D0 (no) 1999-11-24
SG47488A1 (en) 1998-04-17
FI952458L (fi) 1995-05-19
IL107654A0 (en) 1994-02-27
TW294595B (cs) 1997-01-01
SK282378B6 (sk) 2002-01-07
US5674868A (en) 1997-10-07
IL119273A0 (en) 1996-12-05
HU9501476D0 (en) 1995-07-28
EP0669919B1 (en) 1999-01-27
NO307690B1 (no) 2000-05-15
JPH08505840A (ja) 1996-06-25
DK0669919T3 (da) 1999-09-13
FI952458A0 (fi) 1995-05-19
DE69323322D1 (de) 1999-03-11
US5863923A (en) 1999-01-26
PL176051B1 (pl) 1999-03-31
NO951980L (no) 1995-05-19
CZ287262B6 (en) 2000-10-11
DE69323322T2 (de) 1999-09-09
PL309045A1 (en) 1995-09-18
FI952458A7 (fi) 1995-05-19
CA2149044C (en) 2007-04-03
NO951980D0 (no) 1995-05-19
OA10158A (en) 1996-12-18
BG99593A (en) 1995-12-29
NO995762L (no) 1995-05-19
IL119273A (en) 2000-07-16

Similar Documents

Publication Publication Date Title
ZA938676B (en) Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht antagonists
AU6073596A (en) Intermediates useful in the preparation of 5-HT4 receptor antagonists
GB9524157D0 (en) Therapeutic agents
SE0104332D0 (sv) Therapeutic agents
GB9121456D0 (en) Triazole antifungal agents
IL104816A0 (en) Indoles
DE69720715D1 (en) Hexahydro-pyrido (4,3-b)indolderivate als antipsychotische arzneimittel
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
TW261614B (cs)
LTIP1960A (en) Positive inotropic and lusitropic pyrroloquinolinone derivatives, method for preparing thereof, pharmaceutical composition and method for preparing the same
LTIP1450A (en) Azaspiroalkane derivatives,processes for their preparation and pharmaceutical compositions containing them